Association Between Vitamin D Levels and Inflammatory Markers in COVID-19 Patients: A Meta-Analysis of Observational Studies.

What It Covers

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a meta-analysis.

Vitamin D has immunomodulatory properties that can be useful in COVID-19 patients.

The researchers performed a meta-analysis of observational studies to analyze the association of vitamin D levels with the inflammatory markers in COVID-19 patients.

Who the Included Studies Covered

PubMed tags the participants as both men and women.

The researchers searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), the Cochrane Database of Systematic Reviews, and ClinicalTrial.gov for any relevant studies with comparison data reporting vitamin D levels and inflammatory markers in COVID-19 patients.

The inflammatory markers of interest were interleukin-6 (IL-6), C-reactive protein (CRP), ferritin, procalcitonin, erythrocyte sedimentation rate (ESR), lactate dehydrogenase (LDH), fibrinogen and D-dimer.

How the Review Was Done

A literature search was conducted from December 1, 2019, to January 14, 2022.

Vitamin D deficiency was defined by each individual study and ranged from <9.9 ng/mL to <30 ng/mL.

Two independent investigators assessed study eligibility and synthesized the evidence.

What Was Measured

Topics PubMed links to this paper include COVID-19, Dietary Supplements, Systematic Reviews as Topic, Vitamin D and Vitamins.

What This Means in Plain Language

This is a meta-analysis of Vitamin D, K2, Magnesium and Zinc.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2022 (Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques), a journal based in Switzerland.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.